Thrombolysis for acute ischaemic stroke: revisiting the evidence

• Bankstown-Lidcombe Hospital, Locked Mail Bag 1600, Bankstown, NSW 2200.

---

• 1. Szoeke CEI, Parsons MW, Butcher KS, et al. Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital. Med J Aust 2003; 178: 324-328. <eMJA full text>
• 2. Hoffman JR. Tissue plasminogen activator for acute ischemic stroke: is the CAEP position statement too negative? Can J Emerg Med 2001; 3: 183-185.
• 3. The CAEP Committee on Thrombolytic Therapy for Acute Ischemic Stroke. Position statement on thrombolytic therapy for acute ischemic stroke. Ottawa: Canadian Association of Emergency Physicians. Available at: www.caep.ca/002.policies/002-01.guidelines/thrombolytic.htm (accessed Apr 2003).
• 4. Lenzer J. Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign. BMJ 2002; 324: 723-729.
• 5. Hoffman J. Annals supplement on the American Heart Association proceedings. Ann Emerg Med 2001; 38: 605.
• 6. Wardlaw JM, Sandercock PAG, Berge E. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis. Stroke 2003; 34: 1437-1442. [Previously published online 1 May 2003.]
• 7. Hacke W, Brott T, Caplan L, et al. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 1999; 53 (7 Suppl 4): S3-S14.
• 8. Donnan GA, Davis SM. Thrombolytic therapy in ischaemic stroke: do the benefits outweigh the risks? CNS Drugs 1996; 6: 257-262.
• 9. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-1587.
• 10. Donnan GA, Davis SM, Kaste M, for the International Trial Subcommittee of the International Stroke Liaison Committee, American Stroke Association. Recommendations for the relationship between sponsors and investigators in the design and conduct of clinical stroke trials. Stroke 2003; 34: 1041-1045.
• 11. Szoeke CEI, Parsons MW, Butcher KS, et al. Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital. Med J Aust 2003; 178: 324-328. <MJA full text>
• 12. Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the standard treatment with Alteplase to reverse stroke (STARS) study. JAMA 2000; 283: 1145-1150.
• 13. Szoeke CEI, Parsons MW, Butcher KS, et al. Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital. Med J Aust 2003; 178: 324-328.<eMJA full text>
• 14. Mitka M. Tensions remain over tPA for stroke. JAMA 2003; 289: 1363-1364.
• 15. Warlow C, Wardlaw J. Therapeutic thrombolysis for acute ischaemic stroke: what is good for heart attacks is still not good enough for brain attacks. BMJ 2003; 326: 233-234.
• 16. Wardlaw JM, del Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke (Cochrane review). The Cochrane Library, Issue 1 2003. Oxford: Update Software.
• 17. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-1587.
• 18. Lefkopoulou M, Moore D, Ryan L. The analysis of multiple correlated binary outcomes: application to rodent teratology experiments. J Am Stat Assoc 1989; 84: 810-815.
• 19. Szoeke CEI, Parsons MW, Butcher KS, et al. Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital. Med J Aust 2003; 178: 324-328.<eMJA full text>
• 20. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-1587.
• 21. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000; 55: 1649-1655.
• 22. Szoeke CEI, Parsons MW, Butcher KS, et al. Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital. Med J Aust 2003; 178: 324-328.<eMJA full text>
• 23. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-1587.
• 24. Kothari RU, Broderick JP. Intravenous thrombolytic therapy for acute ischemic stroke: results of large, randomised clinical trials. In: Lyden PD, editor. Thrombolytic therapy for stroke. New Jersey: Humana Press, 2001: 141-152.
• 25. Donnan GA, Davis SM, Levi CR. Thrombolysis for acute ischaemic stroke: revisiting the evidence. Med J Aust 2003; 179: 387. <eMJA full text>
• 26. Ingall TJ, O’Fallon WM, Louise TA, et al. Initial findings of the rt-PA acute stroke treatment review panel. Cerebrovasc Dis 2003; 16 Suppl 4: S1-S125.
• 27. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000; 55: 1649-1655.
• 28. Hacke W, Brott T, Caplan L, et al. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 1999; 53 Suppl 4: S3-S14.